"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
Concept/Terms
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
Ribocarbo- Ribocarbo
- ribosepharm Brand of Carboplatin
Nealorin- Nealorin
- Prasfarma Brand of Carboplatin
Neocarbo- Neocarbo
- Neocorp Brand of Carboplatin
Paraplatin- Paraplatin
- Carboplat
- Paraplatine
- Bristol-Myers Squibb Brand of Carboplatin
Carbosin- Carbosin
- Pharmachemie Brand of Carboplatin
Carbotec- Carbotec
- Columbia Brand of Carboplatin
Ercar- Ercar
- Almirall Brand of Carboplatin
Platinwas- Platinwas
- Chiesi Brand of Carboplatin
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in Harvard Catalyst Profiles by year, and whether "Carboplatin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 4 | 5 |
| 1992 | 1 | 3 | 4 |
| 1993 | 3 | 4 | 7 |
| 1994 | 1 | 6 | 7 |
| 1995 | 3 | 6 | 9 |
| 1996 | 1 | 5 | 6 |
| 1997 | 1 | 6 | 7 |
| 1998 | 2 | 6 | 8 |
| 1999 | 2 | 5 | 7 |
| 2000 | 0 | 5 | 5 |
| 2001 | 3 | 8 | 11 |
| 2002 | 2 | 5 | 7 |
| 2003 | 0 | 12 | 12 |
| 2004 | 2 | 5 | 7 |
| 2005 | 4 | 15 | 19 |
| 2006 | 6 | 18 | 24 |
| 2007 | 4 | 6 | 10 |
| 2008 | 4 | 20 | 24 |
| 2009 | 4 | 16 | 20 |
| 2010 | 3 | 19 | 22 |
| 2011 | 3 | 23 | 26 |
| 2012 | 4 | 23 | 27 |
| 2013 | 2 | 14 | 16 |
| 2014 | 2 | 19 | 21 |
| 2015 | 7 | 16 | 23 |
| 2016 | 7 | 16 | 23 |
| 2017 | 5 | 11 | 16 |
| 2018 | 4 | 18 | 22 |
| 2019 | 4 | 18 | 22 |
| 2020 | 4 | 10 | 14 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
-
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro. Int J Mol Sci. 2021 Apr 29; 22(9).
-
Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723.
-
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131.
-
Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 01; 16(1):162-168.
-
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecol Oncol. 2020 12; 159(3):869-876.
-
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020 09 24; 383(13):1218-1230.
-
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. J Urol. 2021 02; 205(2):414-419.
-
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer Med. 2020 10; 9(20):7511-7523.
-
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020 07; 5(4).